Here are a few analogies for aTyr Pharma:

• A development-stage Genentech focused on immune-related therapies for lung diseases and cancer.
• An early-stage Amgen specializing in novel treatments for inflammatory lung diseases and solid tumors.

• efzofitimod: A therapeutic candidate in clinical trials for pulmonary sarcoidosis and other interstitial lung diseases (ILDs).
• ATYR2810: A monoclonal antibody in preclinical development for the treatment of solid tumors.

aTyr Pharma, Inc. (ATYR) is a biotherapeutics company focused on the discovery and development of medicines, with its lead candidates currently in clinical and preclinical development phases. As such, the company does not yet sell products directly to individuals (patients) or to healthcare providers.

Based on the provided information, aTyr Pharma's major customer or strategic partner identified is:

• Kyorin Pharmaceutical Co., Ltd. (Japan)

This relationship is established through a collaboration and license agreement for the development and commercialization of efzofitimod for interstitial lung diseases (ILDs) in Japan.

Sanjay S. Shukla, M.D., M.S. President and Chief Executive Officer, and Director

Dr. Shukla has served as President and Chief Executive Officer of aTyr Pharma since November 2017, having previously been the company's Chief Medical Officer from March 2016 to November 2017. Before joining aTyr Pharma, he worked in an advisory capacity for several companies, including consulting for aTyr from January 2016 to March 2016. From October 2012 to April 2015, Dr. Shukla was Vice President and Global Head of Integrated Medical Services for Novartis, where he was responsible for global medical affairs operations for all general pharma therapies. He also served as Chief Executive Officer of RXMD, a clinical development consultancy that helped advance early-stage drug candidates, from April 2009 to September 2012. Prior to that, he held various roles in clinical development, data analytics, and drug safety at Vifor Pharma and Aspreva Pharmaceuticals (which was acquired by Vifor Pharma).

Jill M. Broadfoot Chief Financial Officer and Principal Accounting Officer

Jill Broadfoot has been the Chief Financial Officer of aTyr Pharma since July 2018. Before rejoining aTyr Pharma (she previously served as VP US Corporate Controller from May 2016 to January 2017 at GW Pharmaceuticals which was later acquired), she served as CFO of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc. from January 2017 to July 2018, where she was instrumental in establishing operations, corporate governance, finance, accounting, and investor relations. From October 2004 to March 2013, Ms. Broadfoot was the CFO of Vical Inc., overseeing finance, investor relations, manufacturing, information technology, human resources, and business development. Her experience also includes various finance positions at DJO Global, Inc., including Vice President of Finance, and a role as an audit manager at Ernst & Young LLP. Ms. Broadfoot currently sits on the board of directors for Talphera, Inc. and Cue Biopharma, and previously served on the boards of Otonomy, Inc. and Angiocrine Biosciences, Inc.

Nancy E. Denyes General Counsel and Corporate Secretary

Nancy E. Denyes serves as the General Counsel and Corporate Secretary for aTyr Pharma.

Leslie Nangle, Ph.D. VP, Research

Dr. Leslie Nangle is the Vice President of Research at aTyr Pharma. She has been a key figure at aTyr Pharma since its early stages, playing a central role in developing the HARS/NRP2 biology that underpins the company's lead therapeutic candidate.

Robert W. Ashworth, Ph.D. VP, Regulatory Affairs

Dr. Robert W. Ashworth holds the position of Vice President of Regulatory Affairs at aTyr Pharma.

The key risks to aTyr Pharma's business primarily revolve around the clinical and regulatory hurdles of its lead drug candidate, its financial standing, and associated legal challenges.

1. Clinical Trial Failure for Lead Candidate Efzofitimod: aTyr Pharma's lead therapeutic candidate, efzofitimod, failed to meet its primary endpoint in the Phase 3 EFZO-FIT study for pulmonary sarcoidosis in September 2025. This significant setback led to an approximate 83% plunge in the company's stock price and raised substantial questions about the drug's future development path, despite the company's plans to engage with the FDA regarding a path forward. The failure of this trial, which was considered the main short-term catalyst, has severely impacted investor confidence and puts the viability of efzofitimod's future in this indication under intense scrutiny.
2. Nasdaq Delisting Risk: As a direct consequence of the dramatic decline in its stock price, aTyr Pharma received a Nasdaq deficiency notice in December 2025. This notice indicated that its common stock had traded below the required $1.00 minimum bid price for 30 consecutive business days. Failure to regain compliance within the stipulated periods could result in the delisting of its shares, which would likely reduce liquidity, increase price volatility, impair access to capital, and diminish overall investor confidence.
3. Securities Class Action Lawsuits: Following the announcement of the failed Phase 3 trial, aTyr Pharma has become the subject of investor class action lawsuits. These lawsuits allege that the company and its executives made materially false and misleading statements about efzofitimod's efficacy to investors, particularly concerning the drug's capability to allow patients to taper steroid usage. This ongoing litigation adds significant legal and financial pressure, creating uncertainty around potential outcomes and further challenging the company's credibility and financial stability.

aTyr Pharma's main products target several significant addressable markets:

• Pulmonary Sarcoidosis: The global pulmonary sarcoidosis market was valued at approximately USD 19.5 billion across the top 7 major markets (US, EU4, UK, and Japan) in 2024. This market is projected to reach USD 60.2 billion by 2035.
• Interstitial Lung Diseases (ILDs):
  • Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD): The therapeutics market size for CTD-ILD in the 7 major markets (7MM: United States, Germany, France, Italy, Spain, United Kingdom, and Japan) was approximately USD 1.498 billion in 2023. The United States alone accounted for about 70% of this market, or approximately USD 1.044 billion in 2023.
  • Chronic Hypersensitivity Pneumonitis: The global hypersensitivity pneumonitis market size was approximately USD 1.68 billion in 2024 and is predicted to grow to around USD 3.02 billion by 2034.
• Solid Tumors: The global solid tumors market size was valued at USD 362.21 billion in 2024 and is projected to reach USD 1557.42 billion by 2032.

1. Potential Commercialization of Efzofitimod for Pulmonary Sarcoidosis in the U.S.: Despite the Phase 3 EFZO-FIT™ study not meeting its primary endpoint of reducing mean daily oral corticosteroid dose, aTyr Pharma observed clinical benefits for efzofitimod across several key secondary efficacy parameters, including improvements in King's Sarcoidosis Questionnaire (KSQ)-Lung score, Fatigue Assessment Scale score, and KSQ-General Health score, as well as complete steroid withdrawal with KSQ-Lung score improvement. The company is scheduled to meet with the FDA in mid-April 2026 to discuss these results and determine the path forward for efzofitimod in pulmonary sarcoidosis. Positive regulatory outcomes from this meeting could pave the way for potential approval and commercial launch within the next 2-3 years, leading to significant product sales. Analyst forecasts anticipate substantial revenue growth for aTyr Pharma in 2027 and 2028, suggesting an expectation of market entry.

2. Milestone Payments and Royalties from Kyorin Pharmaceutical Collaboration in Japan: aTyr Pharma has a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod (known as ATYR1923 or KRP-R120) for interstitial lung diseases (ILDs) in Japan. Under this agreement, aTyr received an $8 million upfront payment and is eligible to receive up to an additional $167 million upon achieving specific development, regulatory, and sales milestones, along with tiered royalties on net sales in Japan. The company has already received over $20 million from this agreement, including milestones, and is eligible for up to an additional $155 million in milestone payments, primarily tied to regulatory and commercial success for sarcoidosis. Further progress in clinical development, regulatory approvals, and eventual sales in Japan would trigger additional milestone payments and royalty revenues for aTyr Pharma within the specified timeframe.

3. Advancement of Efzofitimod in Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD): aTyr Pharma is currently investigating efzofitimod in the Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related interstitial lung disease (SSc-ILD). This study is on track to complete enrollment in the first half of 2026. Positive results from this trial could lead to further clinical development (e.g., Phase 3 studies) and potentially attract new partnerships or expanded indications for efzofitimod, which could generate revenue through future milestone payments, licensing deals, or eventual commercialization, although full market entry for SSc-ILD is likely beyond the immediate 2-3 year horizon.

Capital Allocation Decisions for aTyr Pharma (ATYR)

Share Issuance

• aTyr Pharma has consistently issued shares to fund its operations, with "Net Cash Flow - Issuance (Purchase) of Equity Shares" showing tens of millions of dollars annually over the last few years, including $66.55 million in Q4 2025 and $66.62 million in Q4 2023.
• The number of shares outstanding for aTyr Pharma increased by 25.21% in one year.
• Routine equity compensation, such as stock option grants to executives, has also contributed to share issuance.

Capital Expenditures

• Capital expenditures for aTyr Pharma have been very low, reported at $77,000 for the last 12 months as of March 5, 2026.
• Annual capital expenditures for fiscal year 2024 were $65,000.
• The company's capital expenditures have shown a decreasing trend, with a trailing twelve months (TTM) CapEx CAGR 3YRS (Compound Annual Growth Rate over 3 years) standing at -64.57%.